Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.58 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | FAP | Q12884 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12767539 | 0.92 | DPP4 (0.68) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL12767570 | 0.88 | DPP4 (0.61) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL2662331 | 0.87 | DPP4 (0.58) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL12767534 | 0.86 | DPP4 (0.65) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL8362641 | 0.83 | DPP4 (0.60) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL13317131 | 0.82 | DPP4 (0.67) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL8325488 | 0.81 | DPP4 (0.70) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL12904647 | 0.81 | DPP4 (0.58) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL12767535 | 0.81 | DPP4 (0.68) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL8243586 | 0.80 | DPP4 (0.67) | DPP4DPP8DPP7DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906503-B2 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7728141-B2 | Substituted naphthyridinone derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090176854-A1 | N-[4-((1S)-1-{3-(3,5-Dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl}ethyl)benzoyl]- beta -alanine; type 2 diabetes, hyperglycemia, or insulin resistance | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090069284-A1 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| US-7485732-B2 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK & CO., INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-7390835-B2 | Aralkyl amines as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080076805-A1 | Acyclic Hydrazides as Cannabinoid Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| US-20070088058-A1 | 3-(1(S)(4-chlorobenzyl)-2(S)-((2-hydroxy-2-methyl-1-phenylpropyl)amino)propyl)-benzonitrile; obesity; potentiation; antagonists | MERCK SHARP & DOHME CORP. | 2007-04-19 | — | — | US | disclosed |
| US-20070032517-A1 | Substituted naphthyridinone derivatives | MERCK SHARP & DOHME CORP. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076805-A1 | Acyclic Hydrazides as Cannabinoid Receptor Modulators | CNR1, CNR2, FAAH | DPP4 1050/4885DPP8 2315/4885DPP7 2326/4885 |
| US-20090176854-A1 | N-[4-((1S)-1-{3-(3,5-Dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl}ethyl)benzoyl]- beta -alanine; type 2 diabetes, hyperglycemia, or insulin resistance | GOT2, GOT1, IAPP | DPP4 5/4885DPP8 34/4885DPP7 13/4885 |
| US-20090069284-A1 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | CNR1, CNR2, MAG | DPP4 1435/4885DPP8 2304/4885DPP7 1963/4885 |
| US-20070088058-A1 | 3-(1(S)(4-chlorobenzyl)-2(S)-((2-hydroxy-2-methyl-1-phenylpropyl)amino)propyl)-benzonitrile; obesity; potentiation; antagonists | CNR2, CNR1, CHRNA4 | DPP4 1734/4885DPP8 3701/4885DPP7 2445/4885 |
| US-20070032517-A1 | Substituted naphthyridinone derivatives | CNR1, CNR2, MAG | DPP4 2758/4885DPP8 2453/4885DPP7 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.